With over 10,000 deals and alliances completed in the past five years, the USA is an essential target market for the company and Jim will be responsible for expanding its share of the market.

McCarthy brings with him a wealth of experience including the start-up of strategic therapeutic business units, pharmaceutical marketing, new products introductions and the life cycle management of established products in the oncology, central nervous system and cardiovascular fields.

Essential for his new role, McCarthy’s work has reached over 30 countries and has covered a range of external growth alliance targets; acquisitions, divestments, licensing, research and agreements. He has worked with some highly respected companies such as Bristol-Myers Squibb, Technology Innovations, Eli Lily & Company and the Arthur Young Health Care Consulting Group.

Fintan Walton, CEO of PharmaVentures said; “The USA is the world’s largest player in the pharmaceutical industry and with over 50% of our business already coming from the USA, it is essential that we maximise on its continued growth. Jim’s appointment will further strengthen our existing position in the country; we already have offices in San Francisco and Cincinnati. He has an outstanding and successful business track record, working in fields such as pharmaceuticals, medical device and ethical nutrition.”

– ends –

Charles Macfarlane joins the Board of PharmaVentures as Non-Executive Director. PharmaVentures assists pharmaceutical and biotechnology companies worldwide in all aspects of deal making.

Fintan Walton, CEO of PharmaVentures says, “I am delighted to be welcoming such a high profile and experienced individual to the Board of PharmaVentures. Charles Macfarlane has sat as an advisor for the Board during the past year and his position as a Director will now provide the company with enormous experience as well as valuable contacts in the industry.”

Charles Macfarlane says, “PharmaVentures is a leading transactions company with whom I look forward to working at a key time in its growth”.

Charles’ career with the Procter & Gamble Company spans 40 years, culminating in Heading up the Alliance, Licensing and Acquisition activity of P&G in the Health Care Global Business Unit as Executive Director. In London he was the founding Chairman of British American Business Inc’s. EU Trade and Investment Policy Committee and now serves as the head of the Policy Group. He is a member of the Board and Executive Committee of BABi.

– ends –

In response to growing industry demand, PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a series of training programmes to provide business executives from across the world with the essential skills necessary to manage and negotiate multi-million dollar agreements.

The pharmaceutical industry is constantly changing; with over 2756 deals and alliances completed in 2006 alone so it is essential that negotiators are trained to the highest standard. PharmaVentures is perfectly placed to provide this training and advice through its newly established PharmaDeals Academy.

Working with a range of external and internal advisors on the direction, content and delivery of the programmes PharmaVentures will provide delegates with expertise delivered by market leaders and shapers. The intensive workshops will showcase arenas such as progressive approaches, methods and techniques for the valuation of pharmaceutical products, technologies, alliances and ventures, identification and evaluation of opportunities, business strategy, benchmarking and product pipelines.

Talking about the negotiating successful strategic alliances and calculating their financial terms workshop, Eleanor Herriman, Director, Business Development, Vertex Pharmaceutical, Inc. said; “I had this workshop recommended highly to me by my colleagues. I was really impressed. I thought you did a really good job balancing between the didactic and the exercises. Excellent framework for business development, putting things into practice is when you really learn it.”

Fintan Walton, CEO of PharmaVentures comments, “Our industry is always changing so training is an essential ingredient to its continued success. PharmaVentures can draw on its extensive experience to help shape the future of the industry by building confidence in deal negotiation and valuation. ”

He continues: “We decided to launch the Academy after the continued success of our international workshop programme. We are striving to empower the industry and its people, through our training, in order to derive maximum value from deal making activities.”

PharmaDeals Academy will also launch an Alumni in July 2007, which will be an exclusive networking club for delegates and a forum of senior executives that have access to networking and cutting edge discussions.

PharmaDeals Academy workshops planned for 2007;

Advanced Valuations of Pharmaceutical Strategic Alliances (18 – 19th April, Oxford)

Fundamentals of Valuation (18th April, London Heathrow)

Advanced Valuations of Pharmaceutical Strategic Alliances (4th- 5th May, Boston)

Other locations will include San Francisco, Vancouver and Brisbane.

– ends –

Oxford, UK January 23, 2009 – If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies. By 2012, the merged company will have lost $25bn with products coming off-patent with the current pipeline only replenishing $2.5bn in that time’.

Dr Walton continues, ‘It will be a major distraction to the merged entity and will mean that the merged company will potentially lose the opportunity to buy up biotechnology companies and their pipelines – leaving their competitors to do so. So, post merger, the rich pickings would have gone elsewhere’.

On the positive side, any potential merger would allow Pfizer to gain access to new therapies, for instance to vaccines, and to share in the remaining years of Enbrel, which is co-marketed with Amgen. Pfizer have complementary Central Nervous System (CNS) portfolios, and so the combined company will have a strong CNS presence. Dr Walton says, ‘As a combined company, there would be 20 products in Phase III, which sounds impressive, but they will need to rationalise to make the business work’.

PharmaDeals Review will be reporting on any potential monopoly issues, although the PharmaVentures’ business analysts say there is no obvious bar to any merger going ahead.

Oxford, UK, May 29, 2008

PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector. “PharmaVentures has always strived to make deal-making easier”, says Chief Executive, Fintan Walton,. “For the last 12 years, our PharmaDeals database has been a trusted resource for leading pharmaceutical and biotechnology companies, as well as law firms, financial institutions and universities from around the world. In launching the new PharmaDeals v2 database, we have not only leveraged our unrivalled expert knowledge, but have also made sure we teamed up with world-class database experts, top Web 2.0 technologists and designers to bring to fruition this innovating database. It’s an exciting time for us.”

Managing the development is Steven Renwick, Associate Publisher, a deal-making professional and expert on licensing. Dr Renwick says, “The PharmaDeals database content has always been well-respected, but we wanted to give our customers much more utility, and improve the way data is accessed and presented. This meant that we actually had to break the PharmaDeals database down into its constituent parts and rebuild it from scratch – an exhaustive but rewarding experience. We carefully mapped out new database structures and content, and topped that with a specially crafted search facility. And then, of course, we are putting on all the bells and whistles of any self-respecting Web 2.0 site.”

“We wanted to bring the new benefits of our database to our customers as quickly as possible”, continues Dr Renwick, “and so the best way was to launch a beta version of PharmaDeals v2 and to solicit feedback from our loyal user-base. For us, this launch is also another beginning; we have plans to roll out further advanced features in the coming weeks and months to serve our highly discerning client base.”

The new PharmaDeals v2 is a business and research tool with many applications, including the benchmarking of deals, analyzing competitor activity, tracking development of particular deals, and investigating the landscape of emerging deals and alliances. The database delivers a fresh user interface and a sophisticated search function to navigate 28,000+ deals. New features include mapping of pharmaceutical products according to the recognised, international classification of diseases, as well as an enhanced classification of product types and a rigorous classification of license territories. The development also introduces new personalisation features, including a watch list and associated email alerting service. Customers will now also benefit from flexible delivery options, including IP domain-authenticated access and xml feeds.

All subscribers to the PharmaDeals v2 will receive access to PharmaDeals Review, the online publication and associated article archive that offers users an intelligence layer that augment comprehensive data records. As well as timely, insightful and concise articles on deals news, PharmaDeals Reviews offers contributed feature articles from industry-leading writers. Subscribers also benefit from context-sensitive access to recent and archived videos released by PharmaTelevision, PharmaVentures’ online TV channel, featuring compelling interviews with industry-leading figures.

Fintan Walton concludes, “The news about our new database is spreading fast, and early reaction is highly positive from both our existing clients, and others looking for a premier deals database and intelligence. With PharmaDeals v2, we truly have set a new standard and are extremely proud of this achievement.”

PharmaDeals® is a registered trademark of PharmaVentures Ltd.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company’s core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporations.

– ends –

Oxford, UK, May 21, 2008

PharmaVentures announced today an agreement with Growthink Research, the U.S.-based market research firm, to distribute its Venture Capital database to customers in industry and academic institutions worldwide. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer, says, “As experts in deals and alliances in the pharmaceutical and biotechnology sector, we have in-depth knowledge of the workflows and information needs of business development and licensing executives. Access to comprehensive and reliable financial data is vital, and we are delighted to have forged this partnership to complement our own proprietary PharmaDeals® v2 database”.

Corey Lavinsky, CEO for Growthink Research, adds, “In our work analyzing venture capital activity, we have carefully tracked over 8,800 U.S.-based, venture-funded companies, many within the bioscience industry. Our data is an invaluable resource for companies looking to raise capital or to identify new clients. Working with PharmaVentures will help us target new markets internationally that have a strong and persistent demand for this high quality financial information”.

The new agreement with Growthink Research, and PharmaVentures’ rapid development of its PharmaDeals database, analytical services and customer services, underpins PharmaVentures’ drive to provide information solutions to its customers in top pharmaceutical and biotechnology companies. Anne Vindenes Allen, PharmaDeals’ Chief Operating Officer, says, “Unlike many generic database providers, we have the expertise in-house to work with our customers to solve their specific business issues. Growthink Research’s Venture Capital database, along with our own new services, is another milestone along this track that will help our customers in their decision-making and effectiveness”.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company’s core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporations.

About Growthink Research

Growthink Research is a market research firm that specializes in tracking and analyzing venture captial activity. Its proprietary venture capital database has detailed information on over 8,800 U.S.-based, venture-funded companies, over 17,000 funding transactions and over 90,000 executives, directors and advisors. Companies seeking captial, venture capital firms, investment bankers, and service providers rely on Growthink Research to raise capital, identify and secure new clients, and gain competitive intelligence.

Corey Lavinsky

Growthink Research

28 S. Venice Blvd.

Suite S

Venice, CA 90291

(310) 823-8346

corey@growthinkresearch.com

www.growthinkresearch.com.

– ends –